Tiwari Rohit Kumar, Gupta Chhedi Lal, Bajpai Preeti
Department of Biosciences, Integral University, Lucknow, Uttar Pradesh, India.
Drug Dev Res. 2022 Apr;83(2):222-224. doi: 10.1002/ddr.21662. Epub 2020 Mar 26.
Recent trends in immunotherapy have shown enthusiasm in exploring Toll-like receptors (TLRs) for designing therapeutical interventions against numerous deadly diseases. TLRs are subfamily of pathogen recognition receptor playing pivotal role in innate immunity. TLR9 is one such critical member belonging to intracellular TLRs which is associated with mounting inflammatory response in response to intruders. Explorative studies have shown CG motifs from the prokaryotic origin as activators of TLR9 culminating in the expression of NFκB. These CG rich short stranded DNA sequences have been further delineated into different classes based on their structural specificities and immunomodulatory properties. Here we discuss the progress of how activation of TLR9 can be utilized with novel parasitic CpG islands to function as potential adjuvants specifically against protozoan parasitic diseases primarily visceral leishmaniasis caused by Leishmania donovani.
免疫疗法的最新趋势显示出，在探索Toll样受体（TLRs）以设计针对多种致命疾病的治疗干预措施方面充满热情。TLRs是病原体识别受体的亚家族，在先天免疫中起关键作用。TLR9是属于细胞内TLRs的关键成员之一，与针对入侵者的炎症反应增强有关。探索性研究表明，原核生物来源的CG基序作为TLR9的激活剂，最终导致NFκB的表达。这些富含CG的短链DNA序列根据其结构特异性和免疫调节特性被进一步划分为不同类别。在此，我们讨论如何利用TLR9的激活与新型寄生性CpG岛，作为潜在佐剂专门对抗原生动物寄生虫病，主要是由杜氏利什曼原虫引起的内脏利什曼病的研究进展。
